--- title: "Research suggests that vaccination against COVID via mRNA vaccines may reduce body’s ability to produce key type of antibody." type: "post" post_id: "2337" slug: "research-suggests-that-vaccination-against-covid-via-mrna-vaccines-may-reduce-bodys-ability-to-produce-key-type-of-antibody" canonical: "https://pennyforyourthoughts2.ca/2022/05/27/research-suggests-that-vaccination-against-covid-via-mrna-vaccines-may-reduce-bodys-ability-to-produce-key-type-of-antibody/" markdown_url: "https://pennyforyourthoughts2.ca/2022/05/27/research-suggests-that-vaccination-against-covid-via-mrna-vaccines-may-reduce-bodys-ability-to-produce-key-type-of-antibody.md" json_url: "https://pennyforyourthoughts2.ca/2022/05/27/research-suggests-that-vaccination-against-covid-via-mrna-vaccines-may-reduce-bodys-ability-to-produce-key-type-of-antibody.json" txt_url: "https://pennyforyourthoughts2.ca/2022/05/27/research-suggests-that-vaccination-against-covid-via-mrna-vaccines-may-reduce-bodys-ability-to-produce-key-type-of-antibody.txt" published: "2022-05-27T12:06:22+00:00" modified: "2022-05-27T12:06:22+00:00" author: "penny2" categories: - "Uncategorized" tags: - "Big Pharma" - "Covid" - "Media" - "state sponsored terrorism" - "Technocracy" site_name: "PFYT2" publisher: "" language: "en-US" generator: "easyPress Markdown" generator_version: "1.0.6" --- > **Vaccines against the coronavirus may impair the body’s ability to produce a key type of antibody, thus potentially limiting the immune system’s defenses against mutated strains of the virus, a new study suggests.** > The study draws upon data collected during Moderna’s randomized control trial for its mRNA SARS-CoV-2 vaccine, from July 2020 through March 2021. > > Researchers looked at participants who tested positive for the coronavirus during the trial, comparing serum levels of specific types of antibodies, based on vaccination status, as well as viral load. > > In particular, the study looks at the antibody response to the virus’ nucleocapsid protein core, using the anti-nucleocapsid antibodies levels (anti-N Abs) as a marker for comprehensive immune system response to the virus, as opposed to the narrower response to the spike protein. Variants of SARS-CoV-2 with mutated spike proteins have been a subject of concern for the reliance of vaccinated immunity on antibodies targeting the s-proteins of the original variant. > > As expected, serum levels of the anti-nucleocapsid antibodies varied based on measured viral load in both the placebo and vaccine cohorts, with participants who had higher viral loads found to have higher levels of neutralizing anti-nucleocapsid antibodies. > > **Researchers also found a pronounced difference, however, in the levels of anti-nucleocapsid antibodies between vaccinated participants and members of the placebo cohort, even when the study controlled for viral load.** ***Trial participants who were given the placebo, rather than the vaccine, and became infected during the trial were found to have significantly higher levels of the neutralizing anti-nucleocapsid antibodies than vaccinated participants who had comparable viral loads.*** ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- > Approximately **60% of participants from the placebo cohort who experienced very mild infection, with low viral loads, were found to have anti-nucleocapsid antibodies, compared to roughly 10% of vaccinated subjects.** > > Among those with higher viral loads – qualifying as mild cases, rather than very mild – **71% of the unvaccinated developed anti-nucleocapsid antibodies, compared to just 15% of those in the vaccine group.** > > **Of all unvaccinated subjects who had been diagnosed with the virus during the trial, nearly all (93%) had measurable levels of anti-nucleocapsid antibodies, compared to less than half (40%) of those in the vaccine cohort.** > > “While an increase in seroreversion cannot be ruled out, given the short time frame the more likely explanation is a vaccine-induced reduction in seroconversion,” researchers wrote, suggesting that trial participants given the vaccine had reduced levels of the anti-nucleocapsid antibodies as a direct result of the vaccine’s narrow focus on the spike protein. > > The researchers also hinted that the diminished anti-nucleocapsid antibody response among the vaccinated could lead to undercounting of breakthrough cases, when measured by antibody sampling. > > “Even with frequent serosampling, serosurveys that rely on antibodies to the N protein may underestimate within-community transmission dynamics.” **natural immunity trumps jab induced ‘immunity’**